Jane Street’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-12,178
Closed -$62K 6338
2019
Q4
$62K Buy
+12,178
New +$64.4K ﹤0.01% 4891
2019
Q3
Sell
-23,945
Closed -$148K 6093
2019
Q2
$148K Buy
+23,945
New +$115K ﹤0.01% 4767
2019
Q1
Sell
-24,654
Closed -$104K 5954
2018
Q4
$104K Buy
+24,654
New +$126K ﹤0.01% 4620
2018
Q2
Sell
-48,685
Closed -$363K 5905
2018
Q1
$363K Buy
48,685
+36,391
+296% +$242K ﹤0.01% 3819
2017
Q4
$73K Sell
12,294
-738
-6% -$4.48K ﹤0.01% 4383
2017
Q3
$96K Buy
+13,032
New +$82.8K ﹤0.01% 4275
2017
Q2
Sell
-50,488
Closed -$476K 5094
2017
Q1
$476K Buy
+50,488
New +$504K ﹤0.01% 2940
2016
Q2
Sell
-21,640
Closed -$94K 4811
2016
Q1
$94K Buy
21,640
+3,720
+21% +$16.6K ﹤0.01% 3898
2015
Q4
$110K Buy
+17,920
New +$117K ﹤0.01% 3775
2015
Q3
Sell
-21,052
Closed -$157K 4371
2015
Q2
$157K Buy
+21,052
New +$127K ﹤0.01% 3335
2014
Q4
Sell
-43,559
Closed -$226K 3238
2014
Q3
$226K Buy
43,559
+27,018
+163% +$135K ﹤0.01% 2118
2014
Q2
$71K Buy
+16,541
New +$63.2K ﹤0.01% 2402
2013
Q3
Sell
-19,134
Closed -$85K 3287
2013
Q2
$85K Buy
+19,134
New +$85.9K ﹤0.01% 2472

Other funds holding PGNX

Jane Street's PGNX Position: Q1 2020 in Review

Jane Street sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 12,178 shares — an estimated $62K sold.

Jane Street first reported a position in PGNX in Q2 2013 and held it in 13 quarters. The position peaked at $476K in Q1 2017. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Jane Street reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Jane Street sold 12,178 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $62K.
  • Jane Street first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • Jane Street's Progenics Pharmaceuticals Inc position peaked at $476K in Q1 2017.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Jane Street's 13F filing for Q1 2020, filed 15 May 2020.